|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Abciximab#Adult Indications and Dosage]] |
| {{Abciximab}}
| |
| {{CMG}}; {{AE}} {{SS}}, {{PB}}
| |
| | |
| ==Dosage and Administration==
| |
| | |
| The safety and efficacy of Abciximab have only been investigated with concomitant administration of [[heparin]] and [[aspirin]] as described in clinical studies.
| |
| | |
| In patients with failed PCIs, the continuous infusion of Abciximab should be stopped because there is no evidence for Abciximab efficacy in that setting.
| |
| | |
| In the event of serious bleeding that cannot be controlled by compression, Abciximab and heparin should be discontinued immediately.
| |
| | |
| The recommended dosage of Abciximab in adults is a 0.25 mg/kg intravenous bolus administered 10-60 minutes before the start of [[PCI]], followed by a continuous intravenous infusion of 0.125 μg/kg/min (to a maximum of 10 μg/min) for 12 hours.
| |
| | |
| Patients with [[unstable angina]] not responding to conventional medical therapy and who are planned to undergo PCI within 24 hours may be treated with an Abciximab 0.25 mg/kg intravenous bolus followed by an 18- to 24-hour intravenous infusion of 10 μg/min, concluding one hour after the PCI.
| |
| | |
| ====Instructions for Administration====
| |
| | |
| Parenteral drug products should be inspected visually for particulate matter prior to administration. Preparations of Abciximab containing visibly opaque particles should NOT be used.
| |
| | |
| [[Hypersensitivity]] reactions should be anticipated whenever protein solutions such as Abciximab are administered. [[Epinephrine]], [[dopamine]], [[theophylline]], [[antihistamine]]s and [[corticosteroid]]s should be available for immediate use. If symptoms of an allergic reaction or [[anaphylaxis]] appear, the infusion should be stopped and appropriate treatment given (see WARNINGS: Allergic Reactions).
| |
| | |
| As with all parenteral drug products, aseptic procedures should be used during the administration of Abciximab.
| |
| | |
| Withdraw the necessary amount of Abciximab for bolus injection into a syringe. Filter the bolus injection using a sterile, non-pyrogenic, low protein-binding 0.2 or 5 μm syringe filter (Millipore SLGV025LS or SLSV025LS or equivalent).
| |
| | |
| Withdraw the necessary amount of Abciximab for the continuous infusion into a syringe. Inject into an appropriate container of sterile 0.9% saline or 5% dextrose and infuse at the calculated rate via a continuous infusion pump. The continuous infusion should be filtered either upon admixture using a sterile, non-pyrogenic, low protein-binding 0.2 or 5 μm syringe filter (Millipore SLGV025LS or SLSV025LS or equivalent) or upon administration using an in-line, sterile, non-pyrogenic, low protein-binding 0.2 or 0.22 μm filter (Abbott #4524 or equivalent). Discard the unused portion at the end of the infusion.
| |
| | |
| No incompatibilities have been shown with intravenous infusion fluids or commonly used cardiovascular drugs. Nevertheless, Abciximab should be administered in a separate intravenous line whenever possible and not mixed with other medications.
| |
| | |
| No incompatibilities have been observed with glass bottles or polyvinyl chloride bags and administration sets.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = REOPRO (ABCIXIMAB) INJECTION, SOLUTION [ELI LILLY AND COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=033d4c3b-4630-4256-b8f7-9ed5f15de9a3#nlm34067-9 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |